Dl-Tryptophan

Dl-Tryptophan

SCHEMBL8937030

CSCCC(N)C(=O)O.NC(Cc1c[nH]c2ccccc12)C(=O)O.NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.70
MEN1 O00255 3/20 0.70
KDM4E B2RXH2 3/20 0.70
MAPT P10636 3/20 0.70
LMNA P02545 2/20 0.70
TSHR P16473 2/20 0.70
BLM P54132 2/20 0.70
PMP22 Q01453 2/20 0.70
MPO P05164 1/20 0.70
HIF1A Q16665 1/20 0.70
CTSC P53634 3/20 0.61
APAF1 O14727 1/20 0.53
POLB P06746 1/20 0.53
RECQL P46063 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HSP90AA1 P07900 1/20 0.53
HSP90AB1 P08238 1/20 0.53
LTA4H P09960 1/20 0.53
PLA2G2A P14555 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tryptophan SCHEMBL3827133 1.00 KMT2A (0.70) KMT2AMEN1KDM4EMAPTLMNA
Tryptophan SCHEMBL3863016 0.97 KMT2A (0.65) KMT2AMEN1KDM4EMAPTLMNA
Dl-Tryptophan SCHEMBL2229687 0.96 KMT2A (0.76) KMT2AMEN1KDM4EMAPTLMNA
Tryptophan SCHEMBL2229691 0.96 KMT2A (0.76) KMT2AMEN1KDM4EMAPTLMNA
Dl-Tryptophan SCHEMBL11461241 0.96 KMT2A (0.76) KMT2AMEN1KDM4EMAPTLMNA
Dl-Tryptophan SCHEMBL23924440 0.96 KMT2A (0.76) KMT2AMEN1KDM4EMAPTLMNA
Dl-Tryptophan SCHEMBL27415496 0.95 KMT2A (0.63) KMT2AMEN1KDM4EMAPTLMNA
Dl-Tryptophan SCHEMBL23924534 0.91 KMT2A (0.70) KMT2AMEN1KDM4EMAPTLMNA
Dl-Tryptophan SCHEMBL27596671 0.89 KMT2A (0.67) KMT2AMEN1KDM4EMAPTLMNA
Tryptophan SCHEMBL9903583 0.89 MEN1 (0.55) KMT2AMEN1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013074966-A1 USE OF PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS FOR TREATING CONTRAST -INDUSED NEPHROPATHY THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2013-05-23 WO disclosed
WO-1996029406-A2 NUCLEAR LOCALIZATION FACTOR ASSOCIATED WITH CIRCADIAN RHYTHMS THE ROCKEFELLER UNIVERSITY (US) 1996-09-26 WO disclosed